摘要
目的比较沙库巴曲缬沙坦钠片与硝苯地平控释片治疗慢性肾功能不全合并高血压的临床效果。方法选取2021年7月—2022年7月莆田市第一医院收治的慢性肾功能不全合并高血压患者80例,采用病历号数字表抽签法分组为研究组(n=40)和对照组(n=40)。研究组患者给予沙库巴曲缬沙坦钠片治疗,对照组患者给予硝苯地平控释片治疗,2组均治疗4周。比较2组临床疗效,治疗前后收缩压、舒张压、肾功能指标[尿白蛋白排泄率(UAER)、胱抑素C(CysC)、尿素氮(BUN)及血肌酐(SCr)]、血清炎性因子[C反应蛋白(CRP)、肿瘤坏死因子-α(TNF-α)、白介素-18(IL-18)]与转化生长因子-β1(TGF-β1)水平及不良反应。结果研究组治疗总有效率为95.00%,高于对照组的77.50%(χ2=5.164,P=0.023)。治疗4周后,2组患者收缩压、舒张压较治疗前下降(P均<0.01),但组间比较差异无统计学意义(P>0.05);2组患者UAER及CysC、BUN、SCr水平较治疗前下降,且研究组低于对照组(P<0.05或P<0.01);2组患者血清CRP、TNF-α、IL-18与TGF-β1水平较治疗前下降,且研究组低于对照组(P<0.05或P<0.01)。研究组与对照组不良反应总发生率比较差异无统计学意义(7.50%vs.12.50%,χ2=0.139,P=0.709)。结论慢性肾功能不全合并高血压患者采用沙库巴曲缬沙坦钠片治疗降压效果较佳,可改善患者肾功能,抑制炎性反应,用药安全性较高。
Objective To compare the clinical effect of sacubitril valsartan sodium tablets and nifedipine controlled release tablets in the treatment of chronic renal insufficiency and hypertension.Methods A total of 80 patients with chronic renal insufficiency complicated with hypertension treated in the First Hospital of Putian City from July 2021 to July 2022 were selected.The patients were divided into the study group(n=40)and the control group(n=40)by drawing lots from the medical record number table.The study group was treated with sacubitril valsartan sodium tablets,and the control group was treated with nifedipine controlled release tablets.Two groups were treated for 4 weeks.The clinical efficacy,including systolic blood pressure,diastolic blood pressure,renal function indicators(UAER,CysC,BUN,SCr),serum inflammatory factors(CRP,TNF-α,IL-18)and TGF-β1 levels before and after treatment,and adverse reaction rate were compared between the two groups.Results The total effective rate of treatment in the study group was 95.00%,higher than the 77.50%in the control group(χ2=5.164,P=0.023).After 4 weeks of treatment,the systolic and diastolic blood pressure of the two groups decreased compared to before treatment(P<0.01),but there was no statistically significant difference between the groups(P>0.05);The UAER,CysC,BUN,and SCr in two groups decreased compared to before treatment,and the study group were lower than those of the control group(P<0.05 or P<0.01);The levels of serum CRP,TNF-α,IL-18 and TGF-β1 in two groups decreased compared to before treatment,and the study group were lower than those of the control group(P<0.05 or P<0.01).There was no significant difference in the total incidence of adverse reactions between the study group and the control group(7.50%vs.12.50%,χ2=0.139,P=0.709).Conclusion Sacubitril valsartan sodium tablets have better antihypertensive effect in patients with chronic renal insufficiency and hypertension,which can improve the renal function,inhibit inflammatory reaction,and have higher medication safety.
作者
蔡涵生
CAI Hansheng(Department of Nephrology,the First Hospital of Putian City,Fujian Province,Putian 351100,China)
出处
《临床合理用药杂志》
2024年第8期16-19,共4页
Chinese Journal of Clinical Rational Drug Use
关键词
慢性肾功能不全
高血压
沙库巴曲缬沙坦钠片
硝苯地平控释片
Chronic renal insufficiency
Hypertension
Sacubitril valsartan sodium tablets
Nifedipine controlled release tablets
